{"entity":{"id":"nct02180711","kind":"trial","name":"Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma","aka":[],"tldr":"A phase 1/2 trial of Acalabrutinib, Rituximab, Lenalidomide in hodgkin lymphoma and non-hodgkin lymphoma, run by Acerta Pharma BV, active and no longer recruiting.","summary":"Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma is a phase 1/2 interventional study registered as NCT02180711 by Acerta Pharma BV, with 113 participants enrolled, started 2014-12-29 and due to reach its primary completion in 2023-08-25. Interventions recorded: acalabrutinib, rituximab (IV), Lenalidomide. Conditions listed: Non Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT02180711","url":"https://clinicaltrials.gov/study/NCT02180711"}],"tags":["ctgov-ingest"],"related":[],"cancers":["hodgkin-lymphoma","non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["acalabrutinib","rituximab","lenalidomide"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT02180711","phase":"1/2","setting":"An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma","sponsor":"Acerta Pharma BV","enrolled":113,"outcomes":[]},"route":"/trials/nct02180711/","neighbours":{"cancer":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"drug":[{"id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/"},{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}